Genotypic resistance mutations in treatment-naïve and treatment-experienced patients under widespread use of antiretroviral drugs in Thailand: Implications for further epidemiologic surveillance

Japanese Journal of Infectious Diseases

Volumn 60, Issue 5, 2007, Pages 284-289

  Sukasem, Chonlaphat ^a   Churdboonchart, Vina ^a   Sirisidthi, Kanjana ^a   Riengrojpitak, Suda ^a   Chasombat, Sanchai ^b   Watitpun, Chotip ^a   Piroj, Wantanich ^a   Tiensuwan, Montip ^c   Chantratita, Wasun ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b HIV Care Unit   (Thailand)

^c Mahidol University   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LEUCINE; METHIONINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VALINE;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG USE; FEMALE; GENE SEQUENCE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PREVALENCE; THAILAND; UNINDEXED SEQUENCE; VIRUS CARRIER; VIRUS ISOLATION; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS STRAIN;

EID: 34948875352     PISSN: 13446304     EISSN: None     Source Type: Journal    
DOI: 10.7883/yoken.jjid.2007.284     Document Type: Article

References (36)

1. Phanuphak, P., Locharernkul, C., Panmuong, W., et al. (1985): A report of three cases of AIDS in Thailand. Asian Pac. J. Allergy Immunol., 3, 195-199.
2. Bureau of Epidemiology (2001): Thai Working Groups on HIV/AIDS Projection. Department of Disease Control, Ministry of Public Health, Thailand.
3. Krisintu, K. (2001): Generic production of HIV/AIDS-related drugs in Thailand. In Improving Access to Care in Developing Countries: Lesson from Practice, Research, Resources and Partnerships. The Joint United Nations Programme on HIV/AIDS (UNAIDS).
4. Sutthent, R., Arworn, D., Kaoriangudom, S., et al. (2005): HIV-1 drug resistance in Thailand: before and after national access to antiretroviral program. J. Clin. Virol., 34, 272-276.
5. Rhee, S.Y., Fessel, W.J., Zolopa, A.R., et al. (2005): HIV-1 protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. J. Infect. Dis., 192, 456-465.
6. Jorgensen, L.B., Christensen, M.B., Gerstoft, J., et al. (2003): Prevalence of drug resistance mutations and non-B subtypes in newly diagnosed HIV-1 patients in Denmark. Scan. J. Infect. Dis., 35, 800-807.
7. World Bank (2000): Thailand's Response to AIDS: Building on Success, Confronting the Future. Thailand Social Monitor, 3.
8. Tand, J.W. and Pillay, D. (2004): Transmission of HIV-1 drug resistance. J. Clin. Virol., 30, 1-10.
9. Leigh Brown, A.J., Frost, S.D., Mathews, W.C., et al. (2003): Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. J. Infect. Dis., 187, 683-686.
10. Si, X.F., Huang, H.L., Wei, M., et al. (2004): Prevalence of drug resistance mutations among antiretroviral drug naïve HIV-1- infected patients in China. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi, 18, 308-311 (in Chinese).
11. Wensing, A.M. and Boucher, C.A. (2003): Worldwide transmission of drug-resistant HIV. AIDS Rev., 5, 140-155.
12. Salomon, H., Wainberg, M.A., Bremer, B., et al. (2000): Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. AIDS, 14, F17-F23.
13. Descamps, D., Chaix, M.L., Andre, P., et al. (2005): French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naïve chronically infected patients in 2001-2002. J. Acquired Immune Defic. Syndr., 38, 545-552.
14. Wensing, A.M., David, A., van, de, Vijver., et al. (2005): Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J. Infect. Dis., 192, 958-966.
15. Devereux, H., Youle, M., Johnson, M., et al. (1999): Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS, 13, F123-F127.
16. Verhofstede, C., Wanzeele, F.V, Van, der, Gucht, B., et al. (1999): Interpretation of RTI or a switch from RTI to PI resulted in a fast reappearance of virus strains with a RT-sesitive genotype. AIDS, 13, 2541-2546.
17. Jenwitheesuk, E., Watitpun, W., Vibhagool, A., et al. (2003): Prevalence of genotypic HIV-1 drug resistance in Thailand, 2002. Ann. Clin. Microbiol. Antimicrob., 2, 4.
18. van Buul, C., Cuypers, H. and Lelie, P. (1998): The NucliSense™ Extractor for automated nucleic acid isolation. Infusionsther. Transfusionsmed., 25, 147-151.
19. Kuritzkes, D.R., Grant, R.M., Feorino, P., et al. (2003): Performance characteristics of the TRUGENE HIV-1 Genotyping Kit and the OpenGene DNA Sequencing System. J. Clin. Microbiol., 41, 1594-1599.
20. Johnson, V.A., Brunn, Vezinet, F., Clotet B., et al. (2005): Update of drug resistance mutation in HIV-1: Fall 2005. Top. HIV Med., 13, 125-131.
21. Hsu, L.Y., Subramaniam, R., Bacheler, L., et al. (2005): Characterization of mutatiorr in CRF01Æ virus isolates from antiretroviral treatment-naïve and -experienced patients in Singapore. J. Acquired Immune Defic. Syndr., 38, 5-13.
22. Zhong, P., Kang, L., Pan, Q., et al. (2003): Identification and distribution of HIV type 1 genetic diversity and protease inhibitor resistance-associated mutations in Shanghai, P.R. China. J. Acquired Immune Defic. Syndr., 34, 91-101.
23. Kalish, M.L., Korber, B.T., Pillai, S., et al. (2002): The sequential introduction of HIV-1 subtype B and CRF01Æ in Singapore by sexual transmission: accelerated V3 region evolution in a subpopulation of Asian CRF01Æ viruses. Virology, 304, 311-329.
24. Saeng-Aroon, S., Wichukchinda, N., Myint, L., et al. (2004): Study of antiretroviral drug-resistant HIV-1 genotypes in northern Thailand: role of mutagenically separated polymerase chain reaction as a tool for monitoring zidovudine-resistant HIV-1 in resource-limited settings. J. Acquired Immune Defic. Syndr., 36, 1051-1056.
25. Auswinporn, S., Jenwitheesuk, E., Panburana, P., et al. (2002): Prevalence of HIV-1 drug resistance in antiretroviral-naive pregnant Thai women. Southeast Asian J. Trop. Med. Public Health, 33, 818-821.
26. Babic, D.Z., Zelnikar, M., Seme, K., et al. (2006): Prevalence of antiretroviral drug resistance mutations and HIV-1 non-B subtypes in newly diagnosed drug-naïve patients in Slovenia, 2000-2004. Virus Res., 118, 156-163.
27. Bellocchi, M.C., Forbici F., Palombi L., et al. (2005): Subtype analysis and mutations to antiretroviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: results from the DREAM programme. J. Med. Virol., 76, 452-458.
28. Vergne, L., Kane, C.T., Laurent, C., et al. (2003): Low rate genotypic HIV-1 drug-resistant strains in the Senegalese government initiative of access to antiretroviral therapy. AIDS, 17, S31-S38.
29. Violin, M., Cozzi-lepri, A., Velleca, R., et al. (2004): Transmitted virus with substitutions at position codon 215 and risk of virological failure in antiretroviral naïve patients starting highly active antiretroviral therapy. Antiviral Ther., 7, S136.
30. Lan, N.T., Recordon-Pinson, P., Hung, P.V., et al. (2003): HIV type I isolates from 200 untreated individuals in Ho Chi Minh City (Vietnam): ANRS 1257 Study. Large predominance of CRF01Æ and presence of major resistance mutations to antiretroviral drugs. AIDS Res. Hum. Retroviruses, 19, 925-928.
31. Brindeiro, P.A., Brindeiro, R.M., Mortensen, C., et al. (2002): Testing genotypic and phenotypic resistance in human immunodeficiency virus type 1 isolates of clade B and other clades from children failing antiretroviral therapy. J. Clin. Microbiol., 40, 4512-4519.
32. Yerly, S., Rakik, A., De, Loes, SK., et al. (1998): Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants. J. Virol., 72, 3520-3523.
33. Brenner, B.G., Routy, J.P., Petrella, M., et al. (2002): Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J. Virol., 76, 1753-1761.
34. Delaugerre, C., Morand-Joubert, L., Chaix, ML., et al. (2004): Persistence of multidrug-resistant HIV-1 without antiretroviral treatment 2 years after sexual transmission. Antiviral Ther., 9, 415-421.
35. Hirsch, M.S., Brun-Vezinet, F., Clotet, B., et al. (2003): Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type1: 2003 recommendations of an International AIDS Society-USA Panel. Clin. Infect. Dis., 37, 113-118.
36. Hammer, S.M., Saag, M.S., Schechter, M., et al. (2006): Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA, 296, 827-843.